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ABSTRACT: Treatment of filamentous fungal infections relies on a limited repertoire of
antifungal agents. Compounds possessing novel modes of action are urgently required. N-
myristoylation is a ubiquitous modification of eukaryotic proteins. The enzyme N-
myristoyltransferase (NMT) has been considered a potential therapeutic target in protozoa
and yeasts. Here, we show that the filamentous fungal pathogen Aspergillus fumigatus
possesses an active NMT enzyme that is essential for survival. Surprisingly, partial
repression of the gene revealed downstream effects of N-myristoylation on cell wall
morphology. Screening a library of inhibitors led to the discovery of a pyrazole
sulphonamide compound that inhibits the enzyme and is fungicidal under partially
repressive nmt conditions. Together with a crystallographic complex showing the inhibitor
binding in the peptide substrate pocket, we provide evidence of NMT being a potential
drug target in A. fumigatus.
Aspergillus spp. are ubiquitous filamentous fungi andtogether with three other genera (Candida, Cryptococcus, and
Pneumocystis) account for more than 90% of invasive fungal
infections worldwide.1 While invasive aspergillosis due to A.
fumigatus is estimated to affect over 200 000 people globally
each year, a further 3 million are affected by chronic pulmonary
aspergillosis.1 At present, treatment is limited to three
antifungal classes: polyenes, azoles, and echinocandins.
Voriconazole, introduced in the 1990s, is a third generation
azole and current “gold standard” for invasive disease and has
increased response and survival rates by 15−20%.2 Overall
mortality for invasive disease, however, remains unacceptable at
around 50%.1 Moreover, there are inherent problems with drug
interactions, toxicities, and increasingly reported resistant
strains3,4 necessitating the urgent identification and character-
ization of novel targets against A. fumigatus.
The myristoyl coenzyme A (MCoA)/protein N-myristoyl-
transferase (NMT, EC: 2.3.1.97) catalyzes an irreversible co-
and post-translational covalent attachment of the saturated 14-
carbon fatty acid, myristate, from MCoA to the N-terminal
glycine residue of many eukaryotic and viral proteins.5 N-
myristoylation is abundant in eukaryotic organisms including
protozoa, fungi, and mammals. Membrane targeting and the
function of many proteins in a variety of signal transduction
cascades and other critical cellular functions is NMT depend-
ent.5−7 Structural studies advocate an ordered Bi−Bi reaction
mechanism8 whereby binding of MCoA to NMT opens a “lid”
permitting access to the peptide-binding site. While the MCoA
binding site is highly conserved, NMTs are striking in their
remarkable diversity of peptide substrates.9 Diversity in the
peptide-binding groove has been suggested to offer the
potential of developing species-specific inhibitors.9 As a result,
NMT has been considered as a potential anticancer,10
antiviral,11 and antiparasitic12−14 therapeutic target. A sub-
stantial pool of new chemical starting points for inhibitors of
NMTs from parasites has recently been described.15−21 So far,
NMT in filamentous fungi such as A. fumigatus remains
uncharacterized although orthologues in other fungal patho-
gens such as Candida albicans22 and Cryptococcus neoformans23
are essential for viability. An NMT knockout in C. albicans
resulted in avirulence in a murine model,22 and several
prototype inhibitors have been reported.24−26 Attempts to
develop broad-spectrum antifungal NMT inhibitors were
unsuccessful and are now potentially redundant given
impending improved diagnostics and a developing preference
for targeted narrow spectrum therapy.
At present, there is a dearth of new antifungals in the drug
discovery pipeline. Conclusive validation of novel antifungal
targets from both a chemical and genetic perspective provides a
critical first step in reversing this trend. Here, we show that
NMT is a potential drug target in A. fumigatus.
■ RESULTS AND DISCUSSION
A. fumigatus Possesses an Active NMT Enzyme. In
previous reports, BLAST searches using the Arabidopsis
thaliana NMT127 or Aspergillus nidulans NMT28 sequences
predicted the presence of an nmt gene (AFUA_4G08070) in
the A. fumigatus genome. The gene is 1630 bp in length and
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contains two introns and three exons. The 1479 bp mRNA
encodes a protein of 492 amino acids (UniProt: Q9UVX3)
sharing 50%, 52%, 38%, and 44% sequence identity with the
NMTs of C. albicans, S. cerevisiae, Leishmania major, and Homo
sapiens (Supporting Information Figure 1), respectively.
Alignment of A. fumigatus NMT (AfNMT) with NMT
structures deposited in the Protein Data Bank (PDB) from C.
albicans (1IYL29) suggested truncation of the N-terminal end,
leaving the core catalytic domain intact. Therefore, to increase
the chance of crystallization, the first 85 amino acids were
removed and a truncated AfNMT construct (Δ1−85)
generated covering residues 86−492. AfNMT Δ1−85 was
overexpressed as a GST fusion protein in Escherichia coli,
purified to homogeneity by glutathione sepharose affinity
chromatography followed by proteolysis of the fusion protein
and size-exclusion chromatography, yielding 2 mg of pure
AfNMT per liter of bacterial culture.
AfNMT steady-state kinetics were assessed by a scintillation
proximity assay [SPA30,31] using biotin-tagged cytoskeleton-
associated protein 5.5 (CAP5.5) as the peptide acceptor
substrate. The Km of myristoyl-CoA (MCoA) for AfNMT was
0.8 ± 0.1 μM (Supporting Information Figure 2A) and
comparable to the Km of MCoA previously reported for S.
cerevisiae [1.4 μM32], L. major [1.4 ± 0.3 μM30], and
Trypanosoma brucei [1.8 ± 0.4 μM30]. Likewise, the Km of
Figure 1. Growth phenotype of the NMT strain under varying repressive conditions. (A) Growth of A. fumigatus strains on solid MM supplemented
with 0.1 M glycerol, 0.1 M ethanol, 0.1 M threonine or 55.5 mM, 111 mM, 166.5 mM glucose or YEPD. (B) Growth on solid MM supplemented
with 0.1 M threonine and 0.56 mM, 1.67 mM 3.33 mM, or 5.55 mM glucose. (C) Real time PCR to amplify the tbp and nmt gene from MMT and
MMTG conditions. (D) Growth curve of the WT and NMT strain on MMTG plates.
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peptide CAP5.5 for AfNMT was 22 ± 2 μM (Supporting
Information Figure 2B), similar for T. brucei [11 ± 1 μM30].
nmt Is Essential for Viability of A. fumigatus. Attempts
to construct a deletion mutant by replacing the A. fumigatus
nmt gene with a pyrG selection marker33 and phenotypic rescue
by supplementing the culture medium with myristic acid failed.
Although myristic acid has fully or partially restored the
phenotype in other species where nmt is essential,22,23,28 all our
transformants failed initial screening with this approach.
Instead, a conditional inactivation mutant was constructed by
replacing the native promoter of the nmt gene with the A.
nidulans alcohol dehydrogenase promoter (PalcA) that is
inducible by ethanol, glycerol, or threonine but repressed by
glucose.34 A plasmid containing a 3′ truncation of nmt fused to
PalcA was transformed into A. fumigatus KU80ΔpyrG− to
generate a conditional mutant (from hereon referred to as the
NMT strain) by homologous recombination (Supporting
Information Figure 3A). PCR and Southern blotting (Support-
ing Information Figure 3B−D) verified that in the NMT strain,
the inducible PalcA promoter replaced the native promoter of
the nmt gene.
Growth of the NMT strain was comparable to the WT when
grown under conditions of nmt induction on a solid minimal
medium (MM) containing 0.1 M glycerol, 0.1 M ethanol, or 0.1
M threonine (MMT). However, growth of the NMT strain was
completely inhibited under conditions of nmt repression on
YEPD or MM containing 55.5−166.5 mM glucose after 48 h at
37 °C (Figure 1A). Thus, nmt expression is required for
viability and is an essential gene in A. fumigatus.
nmt Expression Affects A. fumigatus Cell Wall. In order
to investigate the function of the essential nmt gene in A.
fumigatus, various concentrations of threonine (inducer) and
glucose (repressor) were assessed to identify a minimal level of
nmt expression still producing sufficient mycelia for analysis
(Figure 1B). MM with 0.1 M threonine and 0.56 mM glucose
(MMTG) was selected for all subsequent phenotypic analysis.
Under this condition, the transcription of nmt in the NMT
strain was reduced to 39% of the WT (Figure 1C). Growth of
Figure 2. NMT strain sensitivity to chemical reagents and reduction in cell wall thickness. (A) Serial dilutions of conidia from 105 to 102 were
spotted on solid MMTG containing 50 μg mL−1 Calcofluor white, Congo red, or SDS. (B) Cell wall architecture under repressive conditions
(MMTG). I and II are conidia; III and IV are mycelium. Scale bar is 100 nm.
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the NMT strain was retarded compared to the WT (Figure
1D).
Surprisingly, increased sensitivity to agents compromising
the cell wall (Congo red and Calcofluor white) or membrane
(Sodium dodecyl sulfate) were observed under partial
expression of the nmt gene indicative of cell wall defects and
loss of membrane integrity (Figure 2A). Furthermore,
examination of the cell wall ultrastructure by electron
microscopy showed that the conidia of both NMT and WT
strains were indistinguishable (Figure 2B, I and II), but the
hyphal cell wall of the NMT strain was thinner than the WT
(Figure 2B, III and IV).
nmt Is Required for Cell Wall Morphogenesis. Unlike
other fungi such as A. nidulans28 where NMT mutants grew
only at 37 °C, growth of the NMT strain was unaffected by
temperature (37−50 °C) on MMTG plates (Figure 3A). This
suggests that the target proteins of AfNMT appear to be
neither temperature sensitive nor involved in temperature
adaptation mechanisms.
Polarized hyphal growth is essential in filamentous fungi and
thought to be important for pathogenesis. Our NMT strain
showed a marked polar growth defect under conditions of nmt
repression including delayed germination, abnormal develop-
ment, and retention of polarity (Figure 3B). When nmt was
completely repressed in a YEPD medium, the conidia remained
swollen or displayed very short germ tubes (Figure 3B),
indicating NMT is required for germination and hyphal growth.
Distinct to A. fumigatus was the inability of myristic acid
supplementation to fully restore the NMT strain to the WT
phenotype as has been demonstrated for C. albicans, S.
cerevisiae, and C. neoformans.22,23,35 Only short germ tubes
with a ballooned tip or abnormal polarity were evident after 19
h incubation in supplementation medium (Figure 3B).
AfNMT Crystal Structure Reveals a Molecular Handle
on Selectivity. As a first step toward the design of selective
inhibitors, we determined the crystal structure of AfNMT and
compared it to the human enzyme. The purified AfNMT was
cocrystallized with MCoA and the benzofuran compound Ro-
09-4879 that is known to compete for peptide binding in other
NMTs.29 The structure of the inhibitor complex was solved by
molecular replacement using C. albicans NMT (PDB: 1IYK29)
as a search model and refined against 1.9 Å synchrotron
diffraction data (Supporting Information Table 1). No
interpretable electron density was visible for the first 15
residues of the polypeptide chain.
The overall crystal structure of AfNMT consisted of a
monomer of 391 residues (101−492) forming two GCN5 folds
with MCoA bound to AfNMT in a horseshoe conformation
(Figure 4A). To date, crystal structures of NMT from C.
albicans, S. cerevisiae, H. sapiens, L. major, L. donovani, and P.
vivax have been elucidated showing extensive conservation of
the core fold and active site residues (Figure 4B). The structure
of AfNMT reflects the high level of conservation between
species at a primary, secondary, and tertiary sequence level,
showing the highest level of conservation with C. albicans (Cα
RMSD = 1.301 Å with 346 atoms matched) and S. cerevisiae
NMT (Cα RMSD = 0.840 Å with 350 atoms matched).
Although similar to NMT:MCoA structures previously
Figure 3. NMT strain temperature insensitivity and delayed germination. (A) Serial dilutions of 105 to 102 conidia were spotted on MMTG plates
and incubated at 37 °C for 36 or 42 h and 50 °C for 60 h before imaging. (B) Comparison of germination times of the WT and NMT strains in
MMTG, YEPD, or YEPD supplemented with myristic acid (YEPDM). Scale bar is 10 μm.
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Figure 4. Crystal structure of AfNMT complexes with inhibitors. (A) Overall fold of AfNMT (residues 86−492) in complex with MCoA (stick
representation, Cα cyan) and RO-09-4879 (stick representation, Cα green). (B) Representative crystal structures of NMTs. AfNMT shown in gray
cartoon superimposed upon ScNMT (PDB 1IIC, green), LmNMT (PDB 3H5Z, magenta), HsNMT1 (PDB 3IU1, cyan), and PvNMT (PDB 4B10,
orange). (C) Conservation of NMT active site residues. AfNMT backbone shown in gray cartoon with active site side chains shown in stick
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determined, the CoA phosphate group was not coordinated by
the polypeptide due to the truncated construct lacking the
YKFW motif. Electron density for the benzofuran ligand Ro-09-
4879 was observed in the peptide-binding groove of AfNMT
where it competes with acceptor substrate binding (Figure 4A).
Here, it adopts a similar conformation to a CaNMT:benzofuran
complex [PDB 1IYL29]. The peptide binding site of NMT is
highly conserved with minimal sequence differences between
species. However, comparison of the known NMT crystal
structures reveals three nonconserved residues; Ser378 and
Ala391 are conserved apart from C. albicans and S. cerevisiae
species where the corresponding residues are Phe and Ile. The
residue Val389 is unique to AfNMT, and it forms part of a
hydrophobic pocket with Phe155, Leu273, Phe278, Ser378, and
Val432 that accepts the Ro-09-4879 ligand. In other species,
notably human, this residue is a larger leucine (Leu416; Figure
4C,D). Such a difference may be exploitable in the design of
inhibitors to selectively target AfNMT.
Screening-Based Discovery of a Low Nanomolar
AfNMT Inhibitor. Pyrazole sulphonamide ligands act as highly
potent inhibitors against T. brucei NMT (TbNMT).12 A panel
of antitrypanosome NMT inhibitors was screened against
recombinant AfNMT (Supporting Information Table 2), and
the fungicidal effect on A. fumigatus was determined. As shown
in Figure 5, two potent nanomolar pyrazole sulphonamide
inhibitors were identified using the SPA assay with IC50 values
of 23 nM (DDD85646) and 12 nM (DDD86481).
To investigate the binding mode of these compounds, further
crystal structures of AfNMT:MCoA in complex with the
pyrazole sulphonamide inhibitors were solved (Supporting
Information Table 1), demonstrating that they also occupied
the peptide binding site. DDD85646 adopted a similar
conformation to that previously observed in a L. major NMT
complex (PDB 2WSA) used as a model for T. brucei.12
Specifically, the piperazine group interacts with the C-terminal
carboxylate group via two bridging water molecules. The first
water molecule is tightly coordinated by the C-terminal
carboxylate and the phenolic hydroxyl groups of Tyr147 and
Tyr159 while a second water molecule bridges the piperazine
group and the carboxylate (Figure 4E). The biaryl system
makes no specific interactions with the protein and sits on a
hydrophobic surface formed by the side chains of Tyr263 and
Leu457. A significant bend in the molecule introduced by the
sulphonamide allows the pyrazole moiety to penetrate a
hydrophobic pocket. Oxygen atoms of the sulphonamide
interact with the protein through water-bridged interactions
with the side chains of Asn434, His265, and the backbone
amides of Asp454 and Gly455. The trimethyl pyrazole group
sits in the same hydrophobic pocket occupied by the trifluoro-
phenyl group of Ro-09-4897; however the pyrazole forms a
hydrogen bond with the side chain of Ser378 in addition to
strong hydrophobic packing interactions (Figure 4E).
The isobutyl pyrazole derivative DDD86481 has a very
similar binding mode to DDD85646 (Figure 4E). The
sulphonamide, however, sits lower in the active site losing
interaction with Asn434, and the pyrazole group rotates slightly
to accommodate the larger moiety at the 3- position (Figure
4E). As the isobutyl group packs against the side chains of
Phe155, Phe278, Val389, Ala391, and Val432, this explains the
increased potency over DDD85646 by increasing the hydro-
phobic complementarity in this pocket.
DDD86481 Is Fungicidal under Repressed nmt
Expression. Initially, all compounds from Supporting
Information Table 2 were taken for MIC determination in
RPMI medium containing 0.1 M threonine and 0.56 mM
glucose. Only three compounds (DDD86481, DDD90086, and
Ro-09-4879) showed potent inhibition for the NMT mutant.
The fungicidal activity of DDD85646 was >2.5 mM irrespective
of the A. fumigatus strain tested (WT or NMT). Although the
MIC of DDD86481 was 925 μM against the WT (at 0.625
mM, WT showed a mutant morphogenesis phenotype), it
decreased to 116 μM for the NMT strain (Table 1). As this
molecule is more lipophilic than DDD85646, this might
account for marginally increased cell penetration and a lower
MIC. In order to demonstrate target engagement inside the
cell, the chemical labeling technology employing click
Figure 4. continued
representation (C atoms gray). Strictly conserved residues between species are shown for AfNMT only. Where residues are not conserved, they are
shown for all species in stick representation, ScNMT (green), LmNMT (magenta), HsNMT1 (cyan), and PvNMT (orange). (D) Close-up view of
the AfNMT active site, showing the MCoA (Cα cyan) and RO-09-4879 (Cα green). A molecular surface is shown, colored by sequence conservation
with HsNMT1 (gray, identical side chains; purple, nonidentical side chains). (E) Stereoscopic view of the active site of the AfNMT in complex with
DDD85646 and DDD86481. Active site side chains are shown as sticks with gray Cα, whereas the compound is shown as sticks with gold Cα. The
unbiased |Fo| − |Fc| map (2.5 σ) is shown as a green mesh.
Figure 5. Inhibition of AfNMT. (A) Chemical structures of
compounds DDD85646 and DDD86481. (B) Dose response IC50
curves of DDD85646 and DDD86481 against AfNMT using an SPA
assay.
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chemistry with a myristate alkyne derivative13,16,36 was
explored. However, this approach did not work in A. fumigatus
cells, probably because the myristate derivative could not
penetrate the fungal cell wall.
To investigate whether DDD86481 was acting through
inhibition of AfNMT in the NMT strain, MIC values were
determined under different repressive conditions and nmt
transcript levels assessed by quantitative real time PCR. In 0.56
mM glucose medium, nmt transcription was 81% of the WT. As
nmt transcription reduced, DDD86481 efficacy increased with
correlating reductions in MIC (Table 1) to 7 μM with 24% nmt
expression. As a control, the MICs of amphotericin B,
DDD85646, Ro-09-4609, and Ro-09-4879 were unaffected by
nmt transcript levels (Table 1), although the MIC of
DDD90086 was decreased slightly. Nevertheless, there is still
a significant drop in activity of DDD86481 on going from
enzyme to cell. When NMT is normally expressed, there is an
80 000-fold drop in activity; when NMT is expressed at 24%,
there is a 600-fold drop in activity. This could be due to poor
penetration of DDD86481 through the fungal cell wall but
alternatively could be due to the catalytic role of NMT not
being essential or off-target effects of DDD86481.
Concluding Remarks. Early stage drug discovery suffers
high attrition rates, and there are limited immediate offerings in
the antifungal pipeline besides modifications of existing
classes.37 Increased recognition of the clinical burden posed
by chronic pulmonary aspergillosis threatens to place huge
selective pressures on oral azoles (e.g., itraconazole) as they
have been shown to partially alleviate symptoms.38 Con-
sequently, there is profound medical need for alternative classes
ideally with oral formulations. As a step toward this, we
presented evidence that validates AfNMT as a potential drug
target in A. fumigatus showing that protein N-myristoylation
affects cell morphology and integrity of the cell wall, a structure
essential to all pathogenic fungi and absent from the human
cell.
A conditional NMT mutant strain showed that this gene was
essential and also provided insights into the downstream effects
of NMT inhibition on the cell wall of A. fumigatus. Reduced
expression affected cell morphogenesis and cell wall integrity
effects that have not previously been observed in NMT genetic
disruption studies in other organisms. The fungal cell wall is a
dynamic three-dimensional structure composed predominantly
of polysaccharides. The cell wall involves numerous bio-
synthetic pathways and hundreds of proteins for its synthesis
and remodeling. A significant fraction (typically 0.5%) of
eukaryotic proteins are thought to be myristoylated,27 assisting
switching between cytoplasmic and membrane bound states. In
fact, using the MYR Predictor (http://mendel.imp.ac.at/
myristate/SUPLpredictor.htm), 29 proteins from the A.
f umigatus proteome are predicted to be myristoylated
(Supporting Information Table 3). While most proteins are
of unknown function, two classes, namely the G-protein alpha
subunits and the ADP-ribosylation factors, are known
myristoylation substrates.39,40 Myristoylation of G protein
alpha subunits is required for localization to the plasma
membrane and also facilitating formation of a heterotrimer for
G protein signaling.41 As signal transducers, G proteins
influence numerous signaling cascades especially activate the
cyclic-AMP-dependent PKA pathway42 that regulates growth,
development, stress response, morphogenesis, and virulence in
A. fumigatus.43−45 There is also direct evidence that G proteins
regulate cell wall carbohydrate composition in both plants and
other fungi.46−49 One of the ADP-ribosylation factors in A.
nidulans, ArfB, is involved in polarity establishment during
isotropic growth and polarity maintenance during hyphal
extension.50 Three ArfB orthologues (Afu3g12080,
Afu1g11730, and Afu2g10980) in A. fumigatus are predicted
to be myristoylated proteins (Supporting Information Table 3).
Our NMT strain displayed the same polarized growth defect as
the ArfB mutant. In summary, we propose that the G alpha
subunits and these ArfB orthologues account for the changes in
cell wall and defect in morphogenesis in the NMT strain.
Screening a library of compounds identified a 12 nM
AfNMT inhibitor (DDD86481) that targeted the peptide
binding site and interacted with an amino acid side chain that is
different between the fungal and human enzyme. However, this
failed to directly correlate with fungicidal activity against A.
fumigatus (MIC 925 μM). Reducing nmt expression sensitized
the organism to the inhibitor, reducing the MIC to 7 μM, yet
retaining a 600-fold difference between activity on the target in
vitro and the fungal cell, suggesting the need for more potent
and cell-penetrant compounds to pursue full chemical
validation.
Essential gene targets like NMT produce a lethal phenotype
but a significant challenge will be discovering inhibitors that are
highly selective for A. fumigatus. The peptide-binding sites of
the human and A. fumigatus NMTs are exquisitely similar to
only a single amino acid difference (Val389 in AfNMT and
Leu416 in HsNMT1). However, there is evidence from
TbNMT inhibitors that a substantial window of selectivity
can be derived between HsNMT1 and TbNMT despite highly
similar active site structures.12 Recently, further optimized
TbNMT inhibitors not only possessed improved CNS
Table 1. MIC of Inhibitor Compounds against A. fumigatusa
strains WT NMT
growth conditions BMT + 0.56 mM Glc 0.56 mM Glc 3.33 mM Glc 55.5 mM Glc 111 mM Glc
level of NMT repression nmt transcription (%) 100 ± 4 81 ± 10 78 ± 15 29 ± 7 24 ± 1
MIC (mM) DDD86481 0.925 0.116 0.058 0.014 0.007
DDD85646 >2.5 >2.5 ND >2.5 >2.5
DDD90086 >2.5 1.25 ND 0.625 0.625
Ro-09-4609 >2.5 >2.5 ND >2.5 >2.5
Ro-09-4879 0.625 0.625 ND 0.625 0.625
other compounds* >2.5 >2.5 ND ND ND
amphotericin B 0.0017 0.0017 0.0017 0.0017 0.0017
aThe CLSI broth microdilution method was used to determine the MIC (lowest concentration that completely inhibited growth) after 48 h of
incubation at 37 °C. BMT, basic medium plus 0.1 M threonine; Glc, glucose; ND, not determined; *All other compounds listed in the Supporting
Information, Table 2.
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penetrance but also improved selectivity that could be used to
treat stage 2 human African trypanosomiasis.21 Highly potent
Leishmania-selective NMT inhibitors have been identified
either from compound screening15 or with a structure-based
approach.20 More encouragingly, although structure−activity
relationships (SARs) between Plasmodium NMT and HsNMT1
overlap,15 potent and selective Plasmodium NMT inhibitors
have been discovered15 and optimized,18 demonstrating that
even the small conformational differences of single equivalent
tyrosine could be exploited to engineer selectivity over the
human enzyme.17 Therefore, it may be possible to discover
selective A. fumigatus inhibitors based on the structure
differences between AfNMT and HsNMT1 described here.
In summary, we have provided the first comprehensive
characterization of NMT in a filamentous fungal pathogen and
combined genetic, structural, and chemical approaches to
validate AfNMT as a target illustrating NMT dependent
inhibition of A. fumigatus growth. While the genetic work
confirmed NMT is essential for viability in A. fumigatus, the
mutant NMT strain allows controlled gene expression and
provides a research tool for further probing the effects of (i) N-
myristoylation and (ii) host-fungal interactions.
■ METHODS
Construction of the Conditional Inactivation Mutant.
Plasmid pAL3 containing the A. nidulans alcA promoter (PalcA) and
the Neurospora crassa pyr-4 gene as a fungal selectable marker51 was
used to construct a vector replacing the native nmt promoter with PalcA.
An 1120 bp fragment from −50 to +1070 of the nmt genomic DNA
sequence was amplified with primers P3 and P4 (see Supporting
Information Table 4 for all primer sequences) containing a KpnI and
XbaI restriction site, respectively. The PCR-amplified fragment was
cloned into expression vector pAL3 to yield pALnmtN and confirmed
by sequencing. The pALnmtN was transformed into A. fumigatus
strain KU80ΔpyrG− by PEG-mediated fusion of protoplasts52 and
screened for colonies with uridine/uracil autotrophy. The trans-
formants were confirmed by PCR and Southern blot analysis.
For PCR analysis, three sets of primers were designed: primers P5
and P6 for the 1.6 kb nmt gene, P7 and P8 for the 1.2 kb pyr-4 marker,
and P9 and P10 for a 2.5 kb fragment from PalcA to a downstream
region of the nmt gene. For Southern blotting, genomic DNA was
digested with BamHI, separated by electrophoresis and transferred to a
nylon membrane (Zeta-probe+, Bio-Rad). The 1120 bp fragment of
the nmt genomic sequence and a 1.2 kb HindIII fragment of the N.
crassa pyr-4 gene from pAL3 were used as probes. Labeling and
visualization were performed using the DIG DNA labeling and
detection kit (Roche) according to the manufacturer’s instructions.
Crystallization, Data Collection, and Structure Determina-
tion. AfNMT Δ1−85 (20 mg mL−1) was crystallized using the sitting
drop method. Prior to crystallization, AfNMT was incubated with 10
mM myristoylCoA (MCoA). To obtain ligand complexes, AfNMT
was incubated with 10 mM of compound. Crystals grew after 2 days in
a mother liquor of 0.2 M NaCl and 25% (v/v) PEG3350 and were
cryoprotected for flash freezing in liquid nitrogen. Diffraction data
were collected at the European Synchrotron Radiation Facility (ESRF,
Grenoble, France) and all data processed and scaled with HKL
software.53
The AfNMT-MCoA-RO-09-4879 complex structure was solved by
molecular replacement using MOLREP54 from the CCP4 suite
programs55 with the C. albicans NMT structure (PDB: 1IYK29) as a
search model giving a solution with one molecule in the asymmetric
unit. The resulting electron density map was of good quality, allowing
WarpNtrace56 to build virtually all residues except for a few disordered
regions. REFMAC557 was used for further refinement, iterated with
model building using COOT,58 producing a final model with the
statistics shown in Supporting Information Table 1. Other compound
complexes were solved by molecular replacement using the AfNMT-
MCoA-RO-09-4879 structure as a search model. The model for
ligands was not included until their conformations were fully defined
by unbiased |Fo| − |Fc| ϕcalc electron density maps. Ligand structures
and topologies were generated by PRODRG.59 PyMol was used to
generate figures.60
Minimal Inhibitory Concentration (MIC) Assay. Selected
compounds were tested against A. fumigatus (WT [KU80] and
NMT strains) according to the Clinical and Laboratory Standards
Institute (CLSI) M38-A broth microdilution methodology.61 All
compounds were dissolved in DMSO, and the final DMSO
concentration was 2.5% (v/v) in all wells. The MIC end point was
defined as the lowest concentration producing complete inhibition of
growth (MIC100) for all compounds studied. The MIC values for each
compound were determined in triplicate. Amphotericin B (Sigma) and
A. fumigatus ATCC 204305 served as a positive control and the MIC
within the recommended limits of CLSI M38-A.
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